Hemimaxillectomy for the treatment of oral tumors in 69 dogs.
Hemimaxillectomy was performed in 69 dogs for the treatment of benign or malignant maxillary tumors. Eighteen dogs with ameloblastomas had a median disease-free interval of 21.5 months (range, 1 to 76 months), with a 72% 1-year survival time. There was recurrence in three dogs, with metastasis after malignant transformation in one of them. Based on calculated survival curves, seven dogs with squamous cell carcinoma had a median survival time of 19.2 months (range, 2 to 24 months), with a 57% 1-year survival time. There was local recurrence in two dogs. Twenty-three dogs with melanoma had a median survival time of 9.1 months (range, 1 to 46 months), and a 27% 1-year survival time. Twelve dogs died or were euthanatized because of recurrence or metastases. Fifteen dogs with fibrosarcoma had a median survival time of 12.2 months. Eight dogs died or were euthanatized because of recurrence or metastases. Six dogs with osteosarcoma had a median survival time of 4.6 months (range, 1 to 12.5 months), with a 17% 1-year survival time. Five dogs died or were euthanatized for recurrence or metastases. Tumor size or location and type of partial maxillectomy performed did not affect survival.
Wallace
J
J
Department of Surgery, Animal Medical Center, New York, New York 10021.
Matthiesen
D T
DT
Patnaik
A K
AK
D000564:Ameloblastoma / Q000601:surgery / Q000662:veterinary; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000601:surgery / Q000662:veterinary; D004283:Dog Diseases / Q000601:surgery*; D004285:Dogs; D005260:Female; D005354:Fibrosarcoma / Q000601:surgery / Q000662:veterinary; D005500:Follow-Up Studies; D008175:Lung Neoplasms / Q000556:secondary / Q000662:veterinary; D008207:Lymphatic Metastasis; D008297:Male; D008437:Maxilla / Q000601:surgery*; D008441:Maxillary Neoplasms / Q000601:surgery / Q000662:veterinary*; D008545:Melanoma / Q000601:surgery / Q000662:veterinary; D009364:Neoplasm Recurrence, Local / Q000662:veterinary*; D012516:Osteosarcoma / Q000601:surgery / Q000662:veterinary; D011183:Postoperative Complications / Q000662:veterinary; D011379:Prognosis; D016896:Treatment Outcome